Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC
China170 participantsStarted 2018-07-01
Plain-language summary
The purpose of this study is to explore the safety and feasibility of laparoscopic spleen-preserving No. 10 lymph node dissection for patients with advanced middle or upper third gastric cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients age older than 18 years (including 18 years old);
* The primary lesion is located in the upper or middle third of the stomach, including Siewert II type and Siewert III type adenocarcinoma of the esophagogastric junction;
* Pathologically confirmed primary gastric adenocarcinoma by endoscopic biopsy (including papillary, tubular, mucinous, signet ring cell and poorly differentiated adenocarcinoma);
* Preoperative cancer stage cT2-4aN0-3M0 (according to AJCC-7th TNM staging);
* The Eastern Cooperative Oncology Group performance status of 0 or 1;
* The American Society of Anesthesiology classes of I, II or III;
* Signed Informed consent.
Exclusion Criteria:
* Pregnant or lactating women;
* Suffering from severe mental disorder;
* Previous gastrectomy, including endoscopic submucosal dissection and endoscopic mucosal resection;
* Integrated or enlarged lymph node with maximum diameter larger than 3 cm according to preoperative imaging, including significantly enlarged or bulky No. 10 lymph nodes;
* Siewert I type adenocarcinoma of the esophagogastric junction;
* Other malignant diseases (within 5 years);
* Other illnesses needed operation concurrently;
* Complications (bleeding, perforation or obstruction) required emergency surgery due to primary gastric malignancy;
* Pulmonary function tests FEV1 less than 50% of predicted value;
* Patient suffered from bleeding tendency disease such as hemophilia or took anti-coagulant medication due to deep ā¦
What they're measuring
1
the incidence of postoperative complications within 30 days
Timeframe: 30 days
Trial details
NCT IDNCT03708783
SponsorPeking University Cancer Hospital & Institute